Education
About Us
Working with TipRanks
Follow Us
Mabpharm Limited (HK:2181)
:2181
2181 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$0.10 - HK$0.94
Previous CloseN/A
Volume6.00K
Average Volume (3M)818.49K
Market Cap
HK$3.13B
Enterprise ValueHK$2.23B
Total Cash (Recent Filing)HK$89.34M
Total Debt (Recent Filing)HK$293.09M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding4,124,080,000
10 Day Avg. Volume352,400
30 Day Avg. Volume818,490
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$1.00Price Target Upside28.21% Upside
Rating ConsensusHold
Number of Analyst Covering0
Mabpharm Limited News
2181 FAQ
What was Mabpharm Limited’s price range in the past 12 months?
Mabpharm Limited lowest stock price was HK$0.10 and its highest was HK$0.94 in the past 12 months.
What is Mabpharm Limited’s market cap?
Mabpharm Limited’s market cap is HK$3.13B.
When is Mabpharm Limited’s upcoming earnings report date?
Mabpharm Limited’s upcoming earnings report date is Mar 26, 2026 which is in 188 days.
How were Mabpharm Limited’s earnings last quarter?
Mabpharm Limited released its earnings results on Aug 28, 2025. The company reported HK$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.001.
Is Mabpharm Limited overvalued?
According to Wall Street analysts Mabpharm Limited’s price is currently Undervalued.
Does Mabpharm Limited pay dividends?
Mabpharm Limited does not currently pay dividends.
What is Mabpharm Limited’s EPS estimate?
Mabpharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabpharm Limited have?
Mabpharm Limited has 4,124,080,000 shares outstanding.
What happened to Mabpharm Limited’s price movement after its last earnings report?
Mabpharm Limited reported an EPS of HK$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.351%.
Which hedge fund is a major shareholder of Mabpharm Limited?
Currently, no hedge funds are holding shares in HK:2181
Mabpharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
149.18%
12-Months-Change
Fundamentals
Return on Equity
-25.72%
Trailing 12-Months
Asset Growth
15.04%
Trailing 12-Months
Company Description
Mabpharm Limited
Mabpharm Limited (2181) is a biopharmaceutical company focused on the research, development, and commercialization of innovative drugs primarily for the treatment of cancer and autoimmune diseases. The company operates in the pharmaceutical and healthcare sectors and is dedicated to improving patient outcomes through its advanced biologic therapies.
Technical Analysis
Antengene Corporation Limited
―
TOT BIOPHARM International Co. Ltd.
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
SinoMab Bioscience Ltd.
―
Immunotech Biopharm Ltd
―